Myocardial infarction in a patient after orthotopic heart transplantation, causes of development and management features
https://doi.org/10.52727/2078-256X-2022-18-1-81-86
Abstract
This article describes a clinical case of management of a patient with myocardial infarction (MI) who underwent orthopic heart transplantation. The main cause of myocardial infarction in a transplanted heart is cardiac allograft vasculopathy (ICA), a rapidly progressive form of atherosclerosis. The process involves concentric narrowing of the lumen of the coronary arteries, usually occurring from several months to several years after transplantation. Currently, ICA is the limiting factor in the long-term survival of the allograft. According to the registry of the International Society for Heart and Lung Transplantation (ISHLT), angiographic signs of ICA are found in 8–10 % of patients after 1 year, in 20 % after 3 years, in 30 % after 5 years, in 45 % after 8 years, and more than in 50 % after 10 years. This article presents the latest available pathophysiological data on ICA, methods of diagnosis, prevention, management, treatment and further prognosis of myocardial infarction in patients with heart transplants. In addition, a clinical case of a patient with myocardial infarction without ST-segment elevation after orthotopic heart transplantation is described. The authors participated in the development of the concept and design of the article. The manuscript is grounded and verified for the importance of intellectual content. The manuscript was finally approved by the authors for publication. The authors agree to be responsible for all parts of the work.
About the Authors
B. Yu. Taitakova
Altai State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Byiandu Yu. Taitakova, Intern at the department of cardiology and cardiovascular surgery with APE courses
656038, Altai Territory, Barnaul, Lenin av., 40
A. Yu. Serdechnaya
Altai State Medical University of Minzdrav of Russia; Altai Regional Cardiology Dispensary
Russian Federation
Russian Federation
Anastasiya Yu. Serdechnaya, cardiologist of the cardiology department of acute coronary syndrome, assistant of the department of cardiology and cardiovascular surgery with APE courses
656038, Altai Territory, Barnaul, Lenin av., 40
656055, Altai Territory, Barnaul, Malakhov str., 46
I. А. Sukmanova
Altai State Medical University of Minzdrav of Russia; Altai Regional Cardiology Dispensary
Russian Federation
Russian Federation
Irina A. Sukmanova, doctor of medical sciences, head of the cardiology department of acute coronary syndrome, professor of the department of cardiology and cardiovascular surgery with APE courses
656038, Altai Territory, Barnaul, Lenin av., 40
656055, Altai Territory, Barnaul, Malakhov str., 46
References
1. Peter S., Hulme O., Deuse T., Vrtovec B., Fearon W.F., Hunt S., Haddad F. ST-elevation myocardial infarction following heart transplantation as an unusual presentation of coronary allograft vasculopathy: a case report. Transplant. Proc., 2013; 45: 787. doi: 10.1016/j.transproceed.2012.08.021
2. Langstraat M., Musters K.J.S., Manintveld O., Masetti M., Potena L. Coronary artery disease in heart transplantation: new concepts for an old disease. Transpl. Int., 2018; 31 (8): 787–827. doi: 10.1111/tri.13141
3. Stehlik J., Edwards L.B., Kucheryavaya A.Y., Benden C., Christie J.D., Dipchand A.I., Dobbels F., Kirk R., Rahmel A.O., Hertz M.I. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report–2012. J. Heart Lung Transplant., 2012; 31: 1052–1064. doi: 10.1016/j.healun.2012.08.002
4. Colvin-Adams M., Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction. Clin. Transplant, 2011; 25(2): 175–184. doi: 10.1111/j.1399-0012.2010.01307.x
5. Lopez-Sainz A., Barge-Caballero E., Barge-Caballero G., Couto-Mallon D., Paniagua-Martin M.J., Seoane-Quiroga L., Iglesias-Gil C., Herrera-Norena J.M., Cuenca-Castillo J.J., Vazquez-Rodriguez J.M., Crespo-Leiro M.G. Late graft failure in heart transplant recipients: incidence, risk factors and clinical outcomes. Eur. J. Heart Fail., 2018; 20: 385. doi: 10.1002/ejhf.886
6. Lu W.H., Palatnik K., Fishbein G.A., Lai C., Levi D.S., Perens G., Alejos J., Kobashigawa J., Fishbein M.C. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J. Heart Lung Transplant., 2011; 30: 1044–1050. doi: 10.1016/j.healun.2011.04.008
7. Goland S., Czer L.S., Kass R.M., Siegel R.J., Mirocha J., de Robertis M.A., Lee J., Raissi S., Cheng W., Fontana G., Trento A. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J. Am. Coll. Cardiol., 2008; 51: 1214–1220. doi: 10.1016/j.jacc.2007.11.052
8. Jentzer J., Hickey G., Khandhar S. Transplant coronary heart disease: challenges and solutions. Transplant. Res. Risk Manag., 2014; 6: 117–127. doi: 10.2147/TRRM.S50846
9. Russian Society of Cardiology. Acute myocardial infarction with elevation of the ST segment of the electrocardiogram. Clinical Guidelines, 2020. (In Russ.) Российское кардиологическое общество. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации, 2020; 11(25): 3–157. doi: 10.15829/29/1560-4071-2020-4103
10. Miller C.A., Chowdhary S., Ray S.G. Role of noninvasive imaging in the diagnosis of cardiac allograft vasculopathy. Circ. Cardiovasc. Imaging, 2011; 4: 583–593. doi: 10.1161/CIRCIMAGING.110.961425
11. Logani S., Saltzman H.E., Kurnik P., Eisen H.J., Ledley G.S. Clinical utility of intravascular ultrasound in the assessment of coronary allograft vasculopathy: a review. J. Interv. Cardiol., 2011; 24: 9–14. doi: 10.1111/j.1540-8183.2010.00600.x
12. Schmauss D., Weis M. Cardiac allograft vasculopathy: recent developments. Circulation, 2008; 117: 2131–2141. doi: 10.1161/CIRCULATIONAHA.107.711911
13. Crespo-Leiro M.G., Marzoa-Rivas R., Barge-Caballero E., Paniagua-Martin M.J. Prevention and treatment of coronary artery vasculopathy. Curr. Opin. Organ. Transplant., 2012; 17: 546–550. doi: 10.1097/MOT.0b013e3283577fd9
14. Erinc K., Yamani M.H., Starling R.C., Crowe T., Hobbs R., Bott-Silverman C., Rincon G., Young J.B., Feng J., Cook D.J., Smedira N., Tuzcu E.M. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J. Heart Lung Transplant., 2005; 24: 1033–1038. doi: 10.1016/j.healun.2004.06.005
15. Dasari T.W., Hennebry T.A., Hanna E.B., Saucedo J.F. Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature. Catheter Cardiovasc. Interv., 2011; 77: 962–969. doi: 10.1002/ccd.22975
16. Agarwal S., Parashar A., Kapadia S.R., Tuzcu E.M., Modi D., Starling R.C., Oliveira G.H. Long-term mortality after cardiac allograft vasculopathy: implications of percutaneous intervention. JACC Heart Fail., 2014; 2: 281–288. doi: 10.1016/j.jchf.2014.01.003
17. Tjang Y.S., Tenderich G., Hornik L., Korfer R. Cardiac retransplantation in adults: an evidence-based systematic review. Thorac. Cardiovasc. Surg., 2008; 56: 323–327. doi: 10.1055/с-2008-1038662
Review
For citations:
Taitakova B.Yu., Serdechnaya A.Yu., Sukmanova I.А. Myocardial infarction in a patient after orthotopic heart transplantation, causes of development and management features. Ateroscleroz. 2022;18(1):81-86. (In Russ.) https://doi.org/10.52727/2078-256X-2022-18-1-81-86
Views:
397
Email this article 